ALISKIREN HEMIFUMARATE Drug Patent Profile

Which patents cover Aliskiren Hemifumarate, and when can generic versions of Aliskiren Hemifumarate launch?

Aliskiren Hemifumarate is a drug marketed by Ph Health and is included in one NDA.

The generic ingredient in ALISKIREN HEMIFUMARATE is aliskiren hemifumarate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the aliskiren hemifumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aliskiren Hemifumarate

A generic version of ALISKIREN HEMIFUMARATE was approved as aliskiren hemifumarate by PH HEALTH on March 22^nd, 2019.

Summary for ALISKIREN HEMIFUMARATE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	59
Patent Applications:	156
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ALISKIREN HEMIFUMARATE
DailyMed Link:	ALISKIREN HEMIFUMARATE at DailyMed

Pharmacology for ALISKIREN HEMIFUMARATE

Drug Class	Renin Inhibitor
Mechanism of Action	Renin Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ALISKIREN HEMIFUMARATE

C09XA	Renin-inhibitors
C09X	OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

Paragraph IV (Patent) Challenges for ALISKIREN HEMIFUMARATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TEKTURNA	Tablets	aliskiren hemifumarate	150 mg and 300 mg	021985	1	2014-01-27

US Patents and Regulatory Information for ALISKIREN HEMIFUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	ALISKIREN HEMIFUMARATE	aliskiren hemifumarate	TABLET;ORAL	206665-001	Mar 22, 2019	AB	RX	No	No
Ph Health	ALISKIREN HEMIFUMARATE	aliskiren hemifumarate	TABLET;ORAL	206665-002	Mar 22, 2019	AB	RX	No	No

Aliskiren Hemifumarate Market Dynamics, Patent Expiration, and Financial Trajectory

Last updated: September 8, 2026

Aliskiren hemifumarate is a first-in-class oral direct renin inhibitor marketed primarily as Tekturna in the United States and Rasilez in Europe. Novartis commercialized the drug for hypertension, but adoption weakened after the ALTITUDE trial identified safety concerns when aliskiren was used with an ACE inhibitor or angiotensin-receptor blocker in high-risk patients. Regulatory restrictions, limited differentiation versus inexpensive generic antihypertensives, and loss of exclusivity reduced the product to a low-value generic market.

Novartis no longer reports aliskiren as a material standalone product. The drug has no biosimilar exposure because it is a chemically synthesized small molecule. Its principal commercial risks are generic substitution, low prescribing priority, formulation competition, and declining clinical relevance rather than biologic competition.

What is aliskiren hemifumarate and how is it used?

Aliskiren hemifumarate is the fumarate salt of aliskiren, a direct renin inhibitor that reduces conversion of angiotensinogen to angiotensin I. The mechanism acts upstream of ACE inhibitors and angiotensin-receptor blockers in the renin-angiotensin-aldosterone system.

The FDA approved Tekturna tablets in March 2007 for the treatment of hypertension. The product was also developed in combination with hydrochlorothiazide as Tekturna HCT and with amlodipine as Amturnide. Europe used the Rasilez brand for aliskiren products. [1]

Attribute	Aliskiren hemifumarate
Active ingredient	Aliskiren
Salt form	Hemifumarate
Drug class	Direct renin inhibitor
Original developer	Novartis
U.S. brand	Tekturna
European brand	Rasilez
Initial FDA approval	March 2007
Primary indication	Hypertension
Dosage form	Oral tablets
Biologic or small molecule	Small molecule
Current competitive class	Generic antihypertensive
Biosimilar pathway	Not applicable

Aliskiren was intended to provide an alternative to ACE inhibitors and ARBs. Clinical practice did not widely adopt it because those established classes had broader outcome data, lower costs, extensive generic availability, and more familiar prescribing profiles.

When did aliskiren lose exclusivity?

Aliskiren’s U.S. regulatory exclusivity began with its March 2007 approval. New chemical entity exclusivity generally protected the product from abbreviated new drug applications for five years, placing the principal FDA exclusivity barrier in the March 2012 period. Patent protection continued beyond the regulatory exclusivity period for certain claims and formulations.

The commercial protection timeline is therefore best separated into three periods:

Period	Commercial position
2007 to 2011	Branded launch and clinical adoption phase
2012 to early 2020s	Patent-protected but commercially weakened branded product
Early 2020s onward	Generic-market phase with limited branded value

The exact end date for a particular U.S. patent depends on the claim, patent term adjustment, patent-term extension, pediatric exclusivity, and whether the patent covered aliskiren alone or a combination product. FDA Orange Book records should control any product-specific launch analysis. [2]

What patents protect aliskiren hemifumarate?

The aliskiren estate historically included claims directed to:

• The aliskiren chemical structure and related renin-inhibitor compounds.
• Aliskiren hemifumarate and pharmaceutical compositions.
• Oral tablet formulations.
• Combination products containing aliskiren and hydrochlorothiazide.
• Combination products containing aliskiren and amlodipine.
• Methods of treating hypertension through renin inhibition.

The core compound estate is no longer a meaningful commercial barrier in the United States. The remaining value of any later-issued formulation or combination claims is narrower and depends on whether a generic applicant seeks approval for the same dosage form, strength, and labeling.

What formulations are protected by aliskiren patents?

The principal branded formulations were:

1. Tekturna tablets containing aliskiren hemifumarate.
2. Tekturna HCT containing aliskiren and hydrochlorothiazide.
3. Amturnide containing aliskiren, amlodipine, and hydrochlorothiazide.
4. Valturna, an aliskiren and valsartan combination, which Novartis withdrew from the U.S. market after regulatory safety concerns.

Formulation patents can delay approval of a specific combination or dosage form, but they do not necessarily preserve market exclusivity for aliskiren monotherapy. Generic companies may avoid a formulation patent through a different inactive-ingredient system, tablet design, strength, or labeling strategy, subject to FDA requirements and patent litigation risk.

What FDA regulatory events changed aliskiren’s market?

The major market disruption occurred during the ALTITUDE trial. The study evaluated aliskiren added to standard therapy in patients with type 2 diabetes and renal impairment or cardiovascular disease. Novartis stopped the trial in December 2011 after the data-monitoring committee found increased adverse events without evidence of clinical benefit. [3]

The FDA responded in 2012 with labeling changes that:

• Contraindicated aliskiren with ACE inhibitors or ARBs in patients with diabetes.
• Warned against the combination in patients with moderate to severe renal impairment.
• Highlighted risks including hypotension, renal impairment, hyperkalemia, and related complications.
• Reduced confidence in broader combination use of renin-angiotensin system drugs.

The European Medicines Agency imposed comparable restrictions on aliskiren-containing medicines. [4]

These actions did not remove aliskiren’s hypertension indication. They narrowed its practical use and damaged physician confidence. The clinical setback occurred close to the end of the product’s initial exclusivity period, leaving Novartis with limited time to recover development and commercialization costs.

What was the financial trajectory of aliskiren?

Aliskiren generated commercial interest at launch because it introduced a new mechanism into a large hypertension market. Its financial trajectory changed after the ALTITUDE safety findings.

Launch and early commercial period

Novartis positioned Tekturna as a differentiated alternative to ACE inhibitors and ARBs. The company also pursued combination products to increase treatment flexibility and protect market share. Early sales were supported by:

• A large hypertension patient population.
• A premium branded price relative to generic ACE inhibitors and ARBs.
• Combination-product opportunities.
• Novartis’s established cardiovascular sales infrastructure.

The product faced structural limitations from the start. Hypertension treatment was already dominated by inexpensive generic therapies, and direct renin inhibition did not establish a clear outcome advantage.

Post-ALTITUDE decline

The ALTITUDE decision materially reduced the addressable market. Prescribers had less reason to use aliskiren in patients already receiving ACE inhibitors or ARBs, while those patients represented a clinically important part of the target population. The regulatory restrictions also weakened the combination-product strategy.

Novartis annual reports subsequently grouped aliskiren within broader cardiovascular or other product categories rather than presenting it as a major standalone revenue line. That reporting treatment indicates that aliskiren was no longer material to consolidated company revenue. [5]

The financial trajectory can be summarized as follows:

Stage	Revenue dynamics	Main driver
2007 to 2010	Growth from branded launch	New mechanism and sales promotion
2011 to 2012	Sharp deterioration in commercial outlook	ALTITUDE trial stoppage and regulatory warnings
2013 to patent expiry	Declining branded contribution	Safety restrictions, weak differentiation, and generic pressure
Post-expiry	Low-margin generic economics	Multiple suppliers and substitution

No current standalone revenue figure is reported by Novartis for aliskiren hemifumarate. The product should therefore be valued as a mature generic active ingredient rather than as a continuing branded-growth asset.

What is the Orange Book status of Tekturna and aliskiren?

Tekturna was approved under NDA 021985. FDA Orange Book records historically included patent information for the product and related combination products. Orange Book listings are relevant to:

• ANDA filing eligibility.
• Paragraph IV certification timing.
• Potential 30-month stays.
• Patent litigation exposure.
• The distinction between monotherapy and combination-product claims.

The Orange Book does not itself establish that a patent is valid or infringed. It identifies patents submitted by the NDA holder and accepted for listing under FDA rules. Generic applicants may certify that listed patents have expired, will expire, are not infringed, or are invalid. [2]

For current commercial analysis, the core issue is whether an ANDA applicant is challenging a still-enforceable patent covering the exact proposed product. Broad historical references to “Tekturna patents” are insufficient because monotherapy, hydrochlorothiazide combinations, and amlodipine combinations have different patent positions.

Which companies are challenging aliskiren and what is the generic launch risk?

The generic risk is high. Aliskiren is an oral small molecule with no biologic manufacturing barrier, no cold-chain requirement, and no complex delivery device. Generic manufacturers can generally compete through ANDAs rather than the more demanding biologics pathways used for biosimilars.

Potential generic entry scenarios include:

Scenario	Market effect
Authorized generic or one early ANDA entrant	Moderate price erosion
Several ANDA entrants	Rapid price compression
Generic monotherapy plus combination products	Broad substitution across the category
Limited supplier participation	Possible shortages but low average pricing
Brand withdrawal with generic continuation	Generic-only market

The most important commercial question is not whether generic entry is possible. It is whether sufficient demand remains to support multiple suppliers. Aliskiren’s restricted clinical positioning and low treatment priority may limit the size of the addressable market.

Does aliskiren face biosimilar risk?

No. Aliskiren hemifumarate is a chemically synthesized small molecule. Biosimilar concepts under the Public Health Service Act do not apply. Competition proceeds through generic-drug approval and patent certification mechanisms under the Federal Food, Drug, and Cosmetic Act.

How strong is the aliskiren patent estate?

The estate is weak from a current commercial perspective.

Strengths

• Early composition and pharmaceutical-composition patents provided meaningful launch protection.
• Combination products created additional patent and regulatory layers.
• The drug had FDA approval before the major safety restrictions emerged.
• Manufacturing a defined small-molecule tablet is technically straightforward but can still require validated impurity controls.

Weaknesses

• Core compound protection has expired or is no longer commercially decisive.
• The product has no durable biologic or device barrier.
• Formulation claims are narrower than composition claims.
• Generic applicants can pursue non-infringing formulations.
• Clinical restrictions reduced the value of the protected market before full commercial maturity.
• Competing antihypertensive classes have stronger prescribing familiarity and lower cost.

Patent strength should therefore be rated as low for new U.S. investment and low to moderate only for narrow historical litigation questions involving specific combination or formulation claims.

What manufacturing and intellectual-property barriers remain?

The active pharmaceutical ingredient requires control of stereochemistry, salt formation, impurities, and polymorphic behavior. These requirements create ordinary pharmaceutical manufacturing obligations but do not represent a durable barrier comparable with monoclonal antibodies, viral vectors, or complex inhaled products.

Relevant manufacturing considerations include:

• Control of aliskiren hemifumarate crystal form and particle characteristics.
• Reproducible tablet dissolution.
• Stability under commercial storage conditions.
• Control of process-related impurities.
• Bioequivalence across strengths.
• Reliable supply of active pharmaceutical ingredient.

The manufacturing barrier is therefore operational rather than strategic. A supplier with an approved facility and a stable API source can compete without recreating Novartis’s original discovery program.

How does aliskiren compare with ACE inhibitors and ARBs?

Category	Aliskiren	ACE inhibitors	ARBs
Mechanism	Direct renin inhibition	Blocks angiotensin II formation	Blocks angiotensin II receptor
Generic availability	Yes	Extensive	Extensive
Outcome evidence	Narrower	Extensive	Extensive
Combination restrictions	Significant after ALTITUDE	Established clinical use	Established clinical use
Cost position	Weak	Strong	Strong
Prescriber familiarity	Lower	High	High
Commercial outlook	Mature, declining	Stable generic demand	Stable generic demand

Aliskiren’s mechanism is scientifically differentiated, but commercial differentiation requires better outcomes, tolerability, convenience, or pricing. The product did not establish those advantages at scale.

What patent litigation and settlement agreements affect aliskiren?

Historical Paragraph IV activity involving aliskiren and related products was relevant during the period when Novartis still had enforceable listed patents. The commercial importance of those disputes declined as core protection expired and the branded market contracted.

A litigation review should distinguish among:

• Tekturna monotherapy patents.
• Tekturna HCT combination patents.
• Amturnide combination patents.
• Valturna patents.
• Patent challenges involving the active ingredient versus tablet formulation.
• Litigation settlements that permitted entry before nominal patent expiry.

No settlement should be treated as a current market restriction without confirmation of the specific product, patent, entry date, and continuing enforceability. FDA Orange Book data and federal court dockets are the controlling sources for those questions.

What generic entry risks exist for aliskiren?

The highest-risk scenario is a fully generic market with several approved suppliers and no meaningful brand loyalty. Price erosion would be strongest for standard tablet strengths and monotherapy products. Combination products may retain somewhat higher pricing if fewer manufacturers support them, but their clinical demand is smaller.

Commercial risks include:

• Rapid substitution after ANDA approval.
• Low reimbursement and limited formulary preference.
• Reduced physician familiarity.
• Safety-label concerns affecting new prescriptions.
• Sparse promotion by generic manufacturers.
• Supply interruptions if the market supports only a few suppliers.
• Weak return on investment for additional clinical studies.

Revenue exposure to Novartis is minimal relative to the company’s major pharmaceutical franchises. The more relevant financial opportunity lies with generic manufacturers able to supply the product at low cost, not with branded-product relaunch.

Key Takeaways

• Aliskiren hemifumarate is a mature direct renin inhibitor with limited remaining branded value.
• Tekturna received FDA approval in March 2007; five-year NCE exclusivity placed the primary regulatory barrier in the March 2012 period.
• The ALTITUDE trial stoppage and subsequent FDA and EMA restrictions materially weakened demand.
• Core patent protection is no longer a significant U.S. commercial barrier.
• Formulation and combination patents may have had narrower, product-specific relevance.
• Aliskiren is a small molecule and does not face biosimilar competition.
• Generic entry risk is high, while the remaining market is likely low value and price sensitive.
• Novartis does not report current standalone aliskiren revenue as a material line item.
• The patent estate is weak for new investment, licensing, or branded relaunch strategies.
• The principal competitive threat comes from generic ACE inhibitors, ARBs, and generic aliskiren itself.

FAQs

Is aliskiren hemifumarate still marketed in the United States?

Aliskiren products may remain available through generic suppliers, while the original Tekturna brand has little current commercial significance. Availability depends on manufacturer, wholesaler inventory, and FDA product status.

Can aliskiren be combined with losartan or lisinopril?

The FDA labeling restricts aliskiren use with ACE inhibitors or ARBs in patients with diabetes and warns against the combination in patients with renal impairment. Combination treatment requires careful review of the current prescribing information. [1]

Is Tekturna HCT protected by the same patents as Tekturna?

No. Combination products can have different formulation, composition, and method-of-use patents from aliskiren monotherapy. Their Orange Book records and generic entry dates must be analyzed separately.

Does aliskiren have pediatric exclusivity?

Any pediatric exclusivity must be determined from the applicable FDA regulatory and Orange Book records. It should not be inferred solely from the original approval date or the expiration of core compound patents.

Is aliskiren commercially attractive for a generic manufacturer?

Only selectively. The product is technically feasible to manufacture, but demand, reimbursement, supplier competition, and the restricted clinical role can make the market unattractive unless the manufacturer has an efficient API and tablet supply chain.

References

1. U.S. Food and Drug Administration. (2024). Tekturna (aliskiren) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2012). FDA drug safety communication: New warning and contraindication for blood pressure medicines containing aliskiren. FDA.

4. European Medicines Agency. (2012). European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines. EMA.

5. Novartis AG. (2007-2023). Annual reports and financial reports. Novartis.